SMC
SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer
May 22, 2026SMC, amivantamab, lazertinib, lung cancer
The Scottish Medicines Consortium (SMC) has accepted Rybrevant (amivantamab) in combination with Lazcluze (lazertinib) for use within NHS Scotland as …
Scottish Medicines Consortium approves Revlimid for two groups of blood cancer patients
October 14, 2020Research and Development Revlimid, SMC
The Scottish Medicines Consortium (SMC) has accepted Revlimid (lenalidomide) for routine use on NHS Scotland for patients with multiple myeloma …
Bavencio/axitinib combo approved for NHS Scotland in advanced renal cell carcinoma
October 13, 2020Manufacturing and Production, Sales and Marketing Merck, NHS, Pfizer, SMC
The Scottish Medicines Consortium (SMC) has given the go-ahead to Merck KGaA and Pfizer’s combination of their PD-L1 inhibitor immunotherapy …
Scottish Medicines Consortium enables access to treatment for rare inherited bone disorder in children
February 18, 2020Manufacturing and Production Crysvita, Kyowa Kirin, SMC, Scottish Medicine Consortium, nhs scotland
The Scottish Medicines Consortium (SMC) has enabled access to Kyowa Kirin’s Crysvita (burosumab) for the NHS in Scotland to treat …
Scotland approves targetted combination therapy for advanced melanoma
February 11, 2020Manufacturing and Production NHS, SMC, Scotland, UK, advanced melanoma, melanoma
The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic …
Vertex cystic fibrosis drugs become available in Scotland after NHS rejection
September 12, 2019Sales and Marketing SMC, Vertex, cystic fibrosis
Two potentially life-changing cystic fibrosis drugs are to become available for a potential pool of 400 patients in Scotland just …
MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland
September 10, 2019Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma
MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …
SMC gives nod for access to new HIV treatment Dovato
September 10, 2019Manufacturing and Production HIV, SMC
The Scottish Medicines Consortium (SMC) has approved Dovato (dolutegravir/lamivudine) for use on the NHS, allowing treatment of individuals with a …
Scotland turns down Vertex’s Orkambi
August 13, 2019Manufacturing and Production Orkambi, SMC, Scotland, Vertex, cystic fibrosis, pharma
The Scottish Medicines Consortium (SMC) has turned down Vertex’ cystic fibrosis drug Orkambi on the grounds that it is not …
Scottish Medicines Consortium rejects Novartis’ CAR T therapy Kymriah
March 12, 2019Manufacturing and Production Kymriah, NICE, Novartis, SMC, Scotland, UK
Scotland’s cost effectiveness body has refused to fund Novartis’ CAR T therapy Kymriah for adult patients with lymphoma. The Scottish …
Scottish Medicines Consortium approves Verkazia for severe eye condition in children and adolescents
December 12, 2018Research and Development, Sales and Marketing SMC, Santen, Scotland, UK, Verkazia, pharma, vernal keratoconjunctivitis
UK-based pharmaceutical firm Santen has announced that the Scottish Medicines Consortium has awarded approval to its eye drops emulsion Verkazia …
Rare lung cancer drug approved in Scotland
August 14, 2018Manufacturing and Production Cancer, SMC, Scotland, Scottish Medicines Consortium, approval, lung cancer
The Scottish Medicines Consortium has approved Roche’s cancer drug alectinib for the treatment of patients with untreated advanced non-small-cell lung …
SMC reverses decision on Opdivo for kidney cancer
June 12, 2017Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, SMC, opdivo
The Scottish Medicines Consortium (SMC) has performed a U-turn on its decision regarding Opdivo (nivolumab), and will now allow patients …
Scotland recommends Janssen’s Imbruvica for leukaemia
April 11, 2017Manufacturing and Production, Sales and Marketing SMC, imbruvica, leukaemia
Janssen has been celebrating the news that its Imbruvica (ibrutinib) has been recommended by the Scottish Medicines Consortium (SMC) for …
SMC rejects Janssen’s multiple myeloma treatment Darzalex
January 17, 2017Manufacturing and Production, Sales and Marketing Janssen, SMC, darzalex
The Scottish Medicines Consortium (SMC) has decided not to recommend Janssen’s Darzalex (daratumumab) for routine use by NHS Scotland as …
Latest content
FibroFind appoints Lee Borthwick as CEO
